Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review
Stroke Research and Treatment · 2025-01 · 2025 (1)
DOI: 10.1155/srat/6893801 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke Research and Treatment, online erschienen am 18.05.2025. Verfasst von Renju Ravi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Poststroke cognitive impairment (PSCI) refers to any level of cognitive decline occurring after a stroke, ranging from mild to severe impairments, while PSCI with dementia describes a more severe form where the cognitive decline significantly affects daily functioning and meets the clinical criteria for dementia. PSCI occurs in more than half of individuals who have had a stroke. Despite its high prevalence, the pharmacotherapeutic options for PSCI are limited. Several pharmacotherapeutic options like cholinesterase inhibitors (e.g., donepezil, galantamine, and rivastigmine) and N ‐methyl‐ d ‐aspartate receptor antagonists (e.g., memantine) have shown potential in improving cognitive functions. However, their overall effectiveness remains inconsistent across different studies and patient populations. Newer drugs such as citicoline, cilostazol, and antidepressants have shown promise, but further research is needed to validate their efficacy and safety specifically for PSCI management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
- Indian Council of Medical Research-Centre for Ageing and Mental Health, Kolkata, India.
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurology, St. Gregorios Medical Mission Hospital, Parumala, Kerala, India.
ORCID-Profile: Renju Ravi, Saibal Das, Tahir Hakami, Prakash B M, Libby Pushparajan
Zitieren
APA
Ravi, R., Das, S., Hakami, T., B M, P., & Pushparajan, L. (2025). Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review. Stroke Research and Treatment, 2025(1). https://doi.org/10.1155/srat/6893801
Vancouver
Ravi R, Das S, Hakami T, B M P, Pushparajan L. Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review. Stroke Research and Treatment. 2025;2025(1). doi:10.1155/srat/6893801
BibTeX
@article{Ravi2025,
author = {Ravi, Renju and Das, Saibal and Hakami, Tahir and B M, Prakash and Pushparajan, Libby},
title = {Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review},
journal = {Stroke Research and Treatment},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/srat/6893801}
}
EUVIMED